化合物详情

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), Bromophthalein Magenta E, which has an estimated vapor pressure of 1.2X10-14 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase Bromophthalein Magenta E may be removed from the air by wet or dry deposition(SRC). Bromophthalein Magenta E contains chromophores that absorb at wavelengths >290 nm(3) and therefore may be susceptible to direct photolysis by sunlight(SRC).

Using a structure estimation method based on molecular connectivity indices(1), the Koc of Bromophthalein Magenta E can be estimated to be 3.2X10+5(SRC). According to a classification scheme(2), this estimated Koc value suggests that Bromophthalein Magenta E is expected to be immobile in soil. The estimated pKa of Bromophthalein Magenta E is 4.5(3), indicating that this compound will primarily exist in anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4).

An estimated BCF of 7700 was calculated in fish for Bromophthalein Magenta E(SRC), using an estimated log Kow of 6.4(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is very high, provided the compound is not metabolized by the organism(SRC).

An estimated pKa of 4.5(1) indicates Bromophthalein Magenta E will exist almost entirely in the anion form at pH values of 5 to 9 and therefore volatilization from water surfaces or moist soil is not expected to be an important fate process(2). Bromophthalein Magenta E is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 2.2X10-15 mm Hg(SRC), determined from a fragment constant method(3).

A base-catalyzed second-order hydrolysis rate constant of 3.8X10-2 L/mole-sec(SRC) was estimated using a structure estimation method(1); this corresponds to half-lives of 5.8 years and 210 days at pH values of 7 and 8, respectively(1). Bromophthalein Magenta E contains chromophores that absorb at wavelengths >290 nm(2) and therefore may be susceptible to direct photolysis by sunlight(SRC).

Bromophthalein Magenta E's production and use as a pH indicator(1) may result in its release to the environment through various waste streams(SRC).

Occupational exposure to Bromophthalein Magenta E may occur through dermal contact with this compound at workplaces where Bromophthalein Magenta E is produced or used. (SRC)

Bromophthalein Magenta E's production and use as a pH indicator may result in its release to the environment through various waste streams. If released to air, an estimated vapor pressure of 1.2X10-14 mm Hg at 25 °C indicates Bromophthalein Magenta E will exist solely in the particulate phase in the atmosphere. Particulate-phase Bromophthalein Magenta E will be removed from the atmosphere by wet or dry deposition. Bromophthalein Magenta E contains chromophores that absorb at wavelengths >290 nm and therefore may be susceptible to direct photolysis by sunlight. If released to soil, Bromophthalein Magenta E is expected to have no mobility based upon an estimated Koc of 3.2X10+5. The estimated pKa of Bromophthalein Magenta E is 4.5, indicating that this compound will exist almost entirely...

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use...